CVC Fund “Shimadzu Future Innovation Fund” has invested in Persist AI, streamlining pharmaceutical formulation processes with AI and robotics.
Shimadzu Corporation invested in Persist AI Formulation Corp (Persist AI, based in California) through the Corporate Venture Capital (CVC) fund “Shimadzu Future Innovation Fund” (Shimadzu FIF). The company is developing a platform that utilizes AI and robotics to streamline the formulation of pharmaceuticals.
The formulation process, which involves processing the pharmaceutical active ingredients into useful and effective forms, relies on the expertise of skillful engineers, leading to high development costs. Persist AI focuses on injectable formulations, known for their excellent absorption and rapid action, and aims to develop sustained releasing* injectable drugs by optimizing conditions such as the loading density and solubility of active ingredients using its proprietary AI. Additionally, they are developing a system to automate traditional manual processes with robotics.
Shimadzu Corporation has been providing analytical measurement instruments, including liquid chromatographs (LC), to the pharmaceutical industry. Through this investment, we aim to collaborate with Persist AI to develop innovative solutions that contribute to the efficiency and quality enhancement of pharmaceutical manufacturing.
- * Sustained releasing: the property designed for pharmaceutical ingredients to be released slowly.
About Persist AI
| Name | ： | Persist AI Formulation Corp |
| CEO | ： | Karthik Raman |
| Location | ： | 890 Embarcadero Dr, West Sacramento California 95605, USA. |
| Founded | ： | 2022 |
| URL | ： | https://www.persist-ai.com/ |
About Shimadzu FIF
| Name | ： | Shimadzu Future Innovation Investment L.P. |
| Fund Size | ： | JPY 5 billion |
| Fund Term | ： | 10 years |
| General Partner | ： | Global Brain Corporation |
| Limited Partner | ： | Shimadzu Corporation |
| URL | ： | https://www.shimadzu.com/research_and_development/cvc/index.html |
